Abcellera Biologics is trading at $11.22, down 8.67%, amid a sharply lower broader market; no company-specific announcement explaining the November 5 decline was found. - The Nasdaq and S&P 500 are sharply lower, while biotech is up 2.05%, so sector weakness does not appear to explain the move. - The latest listed news is an October 22 investor-conference announcement. Trading is live; volume information was not provided.